 Elizabeth Pomfret
Concepts (484)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 117 | 2023 | 847 | 18.070 |
Why?
| | Living Donors | 70 | 2023 | 319 | 13.540 |
Why?
| | Tissue and Organ Procurement | 26 | 2023 | 248 | 6.200 |
Why?
| | Hepatectomy | 23 | 2023 | 139 | 3.770 |
Why?
| | Donor Selection | 15 | 2023 | 73 | 3.510 |
Why?
| | End Stage Liver Disease | 11 | 2023 | 73 | 2.650 |
Why?
| | Carcinoma, Hepatocellular | 9 | 2023 | 227 | 2.380 |
Why?
| | Liver | 40 | 2023 | 1816 | 2.220 |
Why?
| | Patient Selection | 13 | 2023 | 676 | 2.150 |
Why?
| | Liver Neoplasms | 10 | 2023 | 527 | 2.050 |
Why?
| | Kidney Transplantation | 12 | 2023 | 585 | 1.970 |
Why?
| | Postoperative Complications | 24 | 2023 | 2235 | 1.760 |
Why?
| | Organ Transplantation | 8 | 2023 | 165 | 1.640 |
Why?
| | Tissue Donors | 9 | 2024 | 336 | 1.560 |
Why?
| | Liver Cirrhosis | 7 | 2020 | 245 | 1.490 |
Why?
| | Waiting Lists | 15 | 2023 | 228 | 1.350 |
Why?
| | Tissue and Organ Harvesting | 9 | 2013 | 67 | 1.260 |
Why?
| | Graft Survival | 17 | 2023 | 504 | 1.220 |
Why?
| | Perfusion | 2 | 2024 | 153 | 1.140 |
Why?
| | Laparoscopy | 3 | 2023 | 417 | 1.110 |
Why?
| | Humans | 154 | 2024 | 118974 | 1.080 |
Why?
| | Fatty Liver | 5 | 2023 | 253 | 1.040 |
Why?
| | Hepatitis C, Chronic | 5 | 2022 | 151 | 1.040 |
Why?
| | Liver Diseases | 5 | 2023 | 282 | 0.980 |
Why?
| | Consensus Development Conferences as Topic | 2 | 2020 | 32 | 0.870 |
Why?
| | Graft Rejection | 11 | 2020 | 555 | 0.820 |
Why?
| | Robotic Surgical Procedures | 1 | 2023 | 89 | 0.800 |
Why?
| | Liver Failure | 7 | 2016 | 85 | 0.790 |
Why?
| | Frailty | 1 | 2023 | 116 | 0.740 |
Why?
| | Pain, Postoperative | 3 | 2016 | 211 | 0.730 |
Why?
| | Surgeons | 1 | 2024 | 243 | 0.720 |
Why?
| | Portal Vein | 4 | 2017 | 90 | 0.710 |
Why?
| | United States | 29 | 2023 | 12555 | 0.680 |
Why?
| | Resource Allocation | 4 | 2013 | 38 | 0.670 |
Why?
| | Consensus | 7 | 2024 | 534 | 0.650 |
Why?
| | Immunosuppressive Agents | 6 | 2018 | 681 | 0.640 |
Why?
| | Adult | 61 | 2023 | 31512 | 0.590 |
Why?
| | Hepatic Veins | 5 | 2016 | 31 | 0.590 |
Why?
| | Healthcare Disparities | 5 | 2023 | 496 | 0.570 |
Why?
| | Thrombelastography | 6 | 2023 | 192 | 0.570 |
Why?
| | Treatment Outcome | 29 | 2023 | 9342 | 0.550 |
Why?
| | Antiviral Agents | 4 | 2022 | 654 | 0.550 |
Why?
| | Female | 72 | 2023 | 61565 | 0.550 |
Why?
| | Male | 74 | 2023 | 57801 | 0.550 |
Why?
| | Venous Thrombosis | 1 | 2017 | 147 | 0.540 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2017 | 27 | 0.530 |
Why?
| | Middle Aged | 56 | 2022 | 27617 | 0.530 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 280 | 0.520 |
Why?
| | Blood Coagulation Disorders | 4 | 2022 | 208 | 0.520 |
Why?
| | Biopsy | 9 | 2020 | 1079 | 0.510 |
Why?
| | Transplantation, Homologous | 7 | 2020 | 415 | 0.510 |
Why?
| | Sirolimus | 1 | 2016 | 195 | 0.500 |
Why?
| | Retrospective Studies | 29 | 2023 | 12978 | 0.490 |
Why?
| | Kidney | 6 | 2023 | 1353 | 0.470 |
Why?
| | Biliary Tract Diseases | 2 | 2010 | 35 | 0.460 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 900 | 0.460 |
Why?
| | Tissue Plasminogen Activator | 4 | 2023 | 231 | 0.460 |
Why?
| | Hepacivirus | 7 | 2022 | 230 | 0.440 |
Why?
| | Periodicals as Topic | 1 | 2015 | 191 | 0.440 |
Why?
| | Tomography, X-Ray Computed | 9 | 2017 | 2436 | 0.440 |
Why?
| | Societies, Medical | 2 | 2015 | 703 | 0.420 |
Why?
| | Kidney Failure, Chronic | 3 | 2023 | 516 | 0.410 |
Why?
| | Hepatitis C | 5 | 2022 | 217 | 0.410 |
Why?
| | Immunotoxins | 2 | 2023 | 35 | 0.410 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 109 | 0.410 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 41 | 0.400 |
Why?
| | Transplant Recipients | 6 | 2023 | 148 | 0.380 |
Why?
| | Diphtheria Toxin | 2 | 2021 | 63 | 0.370 |
Why?
| | Allografts | 3 | 2023 | 135 | 0.370 |
Why?
| | Survival Rate | 12 | 2020 | 1720 | 0.360 |
Why?
| | Patient Safety | 1 | 2012 | 281 | 0.350 |
Why?
| | Quality of Life | 7 | 2020 | 2366 | 0.340 |
Why?
| | Blood Coagulation | 5 | 2023 | 219 | 0.340 |
Why?
| | Directed Tissue Donation | 1 | 2008 | 4 | 0.340 |
Why?
| | Biliary Tract | 1 | 2008 | 17 | 0.340 |
Why?
| | Bioethical Issues | 1 | 2008 | 8 | 0.340 |
Why?
| | Liver Regeneration | 3 | 2003 | 34 | 0.340 |
Why?
| | Vascular Surgical Procedures | 1 | 2011 | 262 | 0.330 |
Why?
| | Interpersonal Relations | 1 | 2011 | 345 | 0.330 |
Why?
| | Software | 2 | 2012 | 613 | 0.320 |
Why?
| | Severity of Illness Index | 8 | 2023 | 2674 | 0.320 |
Why?
| | Transplants | 2 | 2022 | 36 | 0.300 |
Why?
| | Risk Factors | 15 | 2023 | 9000 | 0.300 |
Why?
| | Adolescent | 20 | 2020 | 18480 | 0.300 |
Why?
| | Tacrolimus | 3 | 2020 | 151 | 0.300 |
Why?
| | Amyloid Neuropathies, Familial | 1 | 2006 | 8 | 0.290 |
Why?
| | Fibrinolysis | 3 | 2023 | 159 | 0.290 |
Why?
| | Transplantation Immunology | 1 | 2006 | 31 | 0.280 |
Why?
| | Insurance, Life | 1 | 2005 | 2 | 0.270 |
Why?
| | Time Factors | 14 | 2021 | 6412 | 0.270 |
Why?
| | Young Adult | 10 | 2021 | 10793 | 0.270 |
Why?
| | Critical Care | 4 | 2024 | 492 | 0.260 |
Why?
| | International Cooperation | 2 | 2016 | 177 | 0.260 |
Why?
| | Registries | 4 | 2022 | 1810 | 0.260 |
Why?
| | Health Care Rationing | 3 | 2013 | 48 | 0.250 |
Why?
| | Decision Making | 1 | 2011 | 809 | 0.250 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1440 | 0.250 |
Why?
| | Intestines | 2 | 2007 | 332 | 0.250 |
Why?
| | Skin Neoplasms | 2 | 2023 | 762 | 0.240 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 490 | 0.240 |
Why?
| | Solitary Kidney | 1 | 2023 | 9 | 0.240 |
Why?
| | Length of Stay | 3 | 2023 | 1032 | 0.230 |
Why?
| | Sezary Syndrome | 1 | 2023 | 44 | 0.230 |
Why?
| | Risk Assessment | 9 | 2022 | 3057 | 0.230 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 62 | 0.230 |
Why?
| | Follow-Up Studies | 10 | 2020 | 4596 | 0.230 |
Why?
| | Aged | 24 | 2021 | 19657 | 0.230 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2011 | 1185 | 0.220 |
Why?
| | Body Temperature | 1 | 2023 | 215 | 0.220 |
Why?
| | Operative Time | 1 | 2023 | 114 | 0.220 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 32 | 0.220 |
Why?
| | Interleukin-2 | 2 | 2023 | 416 | 0.220 |
Why?
| | Thrombosis | 3 | 2022 | 309 | 0.210 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2023 | 59 | 0.210 |
Why?
| | Death | 3 | 2023 | 105 | 0.210 |
Why?
| | Massachusetts | 2 | 2012 | 141 | 0.200 |
Why?
| | Sodium | 1 | 2022 | 200 | 0.200 |
Why?
| | Informed Consent | 2 | 2016 | 163 | 0.200 |
Why?
| | Antibiotic Prophylaxis | 2 | 2020 | 100 | 0.200 |
Why?
| | Prospective Studies | 11 | 2020 | 6471 | 0.200 |
Why?
| | Predictive Value of Tests | 5 | 2020 | 1868 | 0.200 |
Why?
| | Evidence-Based Medicine | 3 | 2016 | 693 | 0.200 |
Why?
| | Physicians | 2 | 2010 | 794 | 0.200 |
Why?
| | Prothrombin Time | 1 | 2000 | 35 | 0.190 |
Why?
| | Cholangitis, Sclerosing | 3 | 2009 | 75 | 0.190 |
Why?
| | Analgesia, Epidural | 1 | 2000 | 21 | 0.190 |
Why?
| | Temperature | 1 | 2023 | 622 | 0.190 |
Why?
| | Educational Status | 3 | 2022 | 437 | 0.190 |
Why?
| | Bupivacaine | 1 | 2000 | 34 | 0.190 |
Why?
| | Reperfusion | 1 | 2020 | 43 | 0.190 |
Why?
| | Diagnostic Imaging | 2 | 2013 | 294 | 0.190 |
Why?
| | Recurrence | 9 | 2011 | 975 | 0.190 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 173 | 0.190 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2020 | 8 | 0.190 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 40 | 0.180 |
Why?
| | Thymidine Phosphorylase | 1 | 2020 | 12 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 210 | 0.180 |
Why?
| | Anesthetics, Local | 1 | 2000 | 85 | 0.180 |
Why?
| | Choline | 4 | 1989 | 109 | 0.180 |
Why?
| | Cholestasis | 1 | 2023 | 228 | 0.180 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 251 | 0.180 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 84 | 0.180 |
Why?
| | Policy | 1 | 2021 | 133 | 0.180 |
Why?
| | Reproducibility of Results | 4 | 2012 | 2874 | 0.180 |
Why?
| | Viremia | 1 | 2020 | 132 | 0.170 |
Why?
| | Nephrectomy | 1 | 2020 | 162 | 0.170 |
Why?
| | Case-Control Studies | 4 | 2022 | 3171 | 0.170 |
Why?
| | Prognosis | 7 | 2023 | 3443 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2020 | 93 | 0.170 |
Why?
| | Catheterization | 2 | 2023 | 163 | 0.160 |
Why?
| | Amyloid Neuropathies | 1 | 1998 | 1 | 0.160 |
Why?
| | Age Distribution | 2 | 2011 | 362 | 0.160 |
Why?
| | Risk | 3 | 2016 | 853 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2023 | 1974 | 0.160 |
Why?
| | Sex Factors | 2 | 2017 | 1781 | 0.160 |
Why?
| | Obesity, Morbid | 2 | 2020 | 197 | 0.160 |
Why?
| | Telomerase | 1 | 2020 | 207 | 0.160 |
Why?
| | Prevalence | 3 | 2023 | 2326 | 0.160 |
Why?
| | Bile Duct Diseases | 1 | 2017 | 17 | 0.160 |
Why?
| | Resuscitation | 1 | 2020 | 253 | 0.160 |
Why?
| | Phlebography | 1 | 2017 | 40 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2020 | 129 | 0.160 |
Why?
| | Biliary Atresia | 1 | 2020 | 224 | 0.160 |
Why?
| | Premature Birth | 1 | 2021 | 284 | 0.160 |
Why?
| | Bariatric Surgery | 1 | 2020 | 166 | 0.150 |
Why?
| | Reoperation | 6 | 2017 | 557 | 0.150 |
Why?
| | Bile Ducts | 1 | 2017 | 73 | 0.150 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 104 | 0.150 |
Why?
| | Incidental Findings | 1 | 2017 | 80 | 0.150 |
Why?
| | Surveys and Questionnaires | 4 | 2016 | 4708 | 0.150 |
Why?
| | Drug Overdose | 1 | 2021 | 294 | 0.150 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 81 | 0.150 |
Why?
| | Incidence | 5 | 2020 | 2424 | 0.140 |
Why?
| | Child | 7 | 2022 | 19129 | 0.140 |
Why?
| | Cause of Death | 2 | 2021 | 380 | 0.140 |
Why?
| | Disease Progression | 4 | 2019 | 2490 | 0.140 |
Why?
| | Perioperative Care | 1 | 2017 | 132 | 0.140 |
Why?
| | Iron | 1 | 2017 | 248 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2017 | 132 | 0.140 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 734 | 0.140 |
Why?
| | Postoperative Care | 1 | 2017 | 237 | 0.130 |
Why?
| | Cohort Studies | 8 | 2021 | 5116 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1244 | 0.130 |
Why?
| | Postoperative Period | 4 | 2020 | 309 | 0.130 |
Why?
| | Morbidity | 2 | 2013 | 296 | 0.130 |
Why?
| | Parents | 2 | 2020 | 1212 | 0.130 |
Why?
| | Mycophenolic Acid | 2 | 2014 | 79 | 0.130 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 51 | 0.130 |
Why?
| | Cadaver | 3 | 2015 | 327 | 0.130 |
Why?
| | Monitoring, Physiologic | 2 | 1994 | 272 | 0.130 |
Why?
| | Costs and Cost Analysis | 2 | 2005 | 202 | 0.130 |
Why?
| | Antilymphocyte Serum | 1 | 2014 | 66 | 0.130 |
Why?
| | Organ Size | 2 | 2012 | 460 | 0.130 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 417 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 647 | 0.120 |
Why?
| | Withholding Treatment | 1 | 2014 | 67 | 0.120 |
Why?
| | Mitochondria | 1 | 2020 | 786 | 0.120 |
Why?
| | Comorbidity | 1 | 2019 | 1527 | 0.120 |
Why?
| | Choline Deficiency | 3 | 1991 | 12 | 0.120 |
Why?
| | Steroids | 1 | 2014 | 153 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2014 | 278 | 0.120 |
Why?
| | Splenorenal Shunt, Surgical | 2 | 2006 | 6 | 0.120 |
Why?
| | Anticoagulants | 1 | 2017 | 559 | 0.110 |
Why?
| | Physician Executives | 1 | 2013 | 37 | 0.110 |
Why?
| | Anesthesiology | 1 | 2013 | 39 | 0.110 |
Why?
| | Data Collection | 2 | 2013 | 658 | 0.110 |
Why?
| | Thoracic Injuries | 1 | 1993 | 63 | 0.110 |
Why?
| | Cooperative Behavior | 1 | 2015 | 408 | 0.110 |
Why?
| | Catheterization, Central Venous | 1 | 1994 | 95 | 0.110 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1284 | 0.110 |
Why?
| | Mental Health | 1 | 2018 | 568 | 0.110 |
Why?
| | Personnel Selection | 1 | 2013 | 71 | 0.110 |
Why?
| | Therapeutic Equipoise | 1 | 2011 | 2 | 0.100 |
Why?
| | Liver Function Tests | 2 | 2020 | 107 | 0.100 |
Why?
| | Catheter Ablation | 1 | 2015 | 286 | 0.100 |
Why?
| | Anastomosis, Surgical | 1 | 2011 | 146 | 0.100 |
Why?
| | Religion | 1 | 2011 | 68 | 0.100 |
Why?
| | Body Mass Index | 1 | 2019 | 2092 | 0.100 |
Why?
| | Family Relations | 1 | 2011 | 85 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 2 | 2011 | 842 | 0.100 |
Why?
| | Observer Variation | 1 | 2011 | 309 | 0.100 |
Why?
| | Health Status Indicators | 1 | 2011 | 154 | 0.100 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.090 |
Why?
| | Critical Illness | 1 | 2015 | 662 | 0.090 |
Why?
| | Wounds, Nonpenetrating | 1 | 1993 | 285 | 0.090 |
Why?
| | Hypertension, Portal | 1 | 2010 | 67 | 0.090 |
Why?
| | Constriction, Pathologic | 2 | 2023 | 203 | 0.090 |
Why?
| | Specialties, Surgical | 1 | 2011 | 76 | 0.090 |
Why?
| | Mutation | 1 | 2020 | 3457 | 0.090 |
Why?
| | North America | 2 | 2023 | 266 | 0.090 |
Why?
| | S-Adenosylmethionine | 1 | 1989 | 49 | 0.090 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2009 | 53 | 0.090 |
Why?
| | Life Expectancy | 1 | 2009 | 52 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1125 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 827 | 0.080 |
Why?
| | Models, Biological | 2 | 2006 | 1715 | 0.080 |
Why?
| | Rats, Inbred Strains | 7 | 1991 | 394 | 0.080 |
Why?
| | Methionine | 1 | 1989 | 145 | 0.080 |
Why?
| | General Surgery | 1 | 2010 | 134 | 0.080 |
Why?
| | Ventilator Weaning | 1 | 2008 | 33 | 0.080 |
Why?
| | Hepatitis, Autoimmune | 3 | 2006 | 33 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 521 | 0.080 |
Why?
| | Guidelines as Topic | 1 | 2010 | 262 | 0.080 |
Why?
| | Lithium | 1 | 1988 | 41 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 740 | 0.080 |
Why?
| | Pulmonary Artery | 1 | 1994 | 1063 | 0.080 |
Why?
| | Immunoglobulin G | 1 | 2011 | 788 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 653 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 667 | 0.080 |
Why?
| | Heart Failure | 1 | 2020 | 1969 | 0.070 |
Why?
| | Prealbumin | 1 | 2006 | 23 | 0.070 |
Why?
| | Hypotension | 1 | 2008 | 120 | 0.070 |
Why?
| | Parenteral Nutrition, Total | 2 | 2003 | 39 | 0.070 |
Why?
| | Survival Analysis | 4 | 2015 | 1267 | 0.070 |
Why?
| | Safety | 1 | 2008 | 304 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2009 | 1223 | 0.070 |
Why?
| | Demography | 1 | 2007 | 274 | 0.070 |
Why?
| | Esophageal and Gastric Varices | 1 | 2006 | 40 | 0.070 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2006 | 109 | 0.070 |
Why?
| | Transplantation | 1 | 2005 | 26 | 0.060 |
Why?
| | Pain | 2 | 2022 | 735 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1200 | 0.060 |
Why?
| | Algorithms | 2 | 2011 | 1541 | 0.060 |
Why?
| | Employment | 1 | 2005 | 135 | 0.060 |
Why?
| | Xanthomatosis | 1 | 2004 | 11 | 0.060 |
Why?
| | Depression | 2 | 2018 | 1132 | 0.060 |
Why?
| | Animals | 11 | 2023 | 33381 | 0.060 |
Why?
| | Granuloma | 1 | 2004 | 87 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2014 | 1774 | 0.060 |
Why?
| | Bilirubin | 1 | 2023 | 95 | 0.060 |
Why?
| | Patient Care | 1 | 2004 | 105 | 0.060 |
Why?
| | Infant | 3 | 2021 | 8293 | 0.060 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2003 | 18 | 0.060 |
Why?
| | Perioperative Period | 1 | 2022 | 51 | 0.060 |
Why?
| | Laboratories | 1 | 2023 | 97 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 344 | 0.050 |
Why?
| | Platelet Count | 1 | 2022 | 83 | 0.050 |
Why?
| | Research | 1 | 2006 | 411 | 0.050 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2002 | 19 | 0.050 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 82 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2009 | 1753 | 0.050 |
Why?
| | Platelet Transfusion | 1 | 2022 | 68 | 0.050 |
Why?
| | RNA, Viral | 3 | 2013 | 572 | 0.050 |
Why?
| | Family | 1 | 2005 | 585 | 0.050 |
Why?
| | Patients | 1 | 2023 | 175 | 0.050 |
Why?
| | Hypophosphatemia | 1 | 2001 | 21 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 491 | 0.050 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 66 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 55 | 0.050 |
Why?
| | Mice | 3 | 2023 | 15520 | 0.050 |
Why?
| | Computer Systems | 1 | 2020 | 47 | 0.050 |
Why?
| | Pancreas | 1 | 2023 | 282 | 0.050 |
Why?
| | Histocompatibility Testing | 1 | 2020 | 123 | 0.050 |
Why?
| | Viscosity | 1 | 2020 | 83 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2021 | 5255 | 0.050 |
Why?
| | Receptors, CCR4 | 1 | 2020 | 16 | 0.050 |
Why?
| | Thymidine | 1 | 2020 | 62 | 0.050 |
Why?
| | Preoperative Care | 1 | 2022 | 332 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 333 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 81 | 0.050 |
Why?
| | Rats | 7 | 1991 | 5392 | 0.050 |
Why?
| | Kidney Function Tests | 1 | 2020 | 164 | 0.050 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 71 | 0.050 |
Why?
| | Esophageal Motility Disorders | 1 | 2020 | 24 | 0.050 |
Why?
| | Remission Induction | 1 | 2020 | 247 | 0.050 |
Why?
| | HLA-DR Antigens | 1 | 2020 | 224 | 0.040 |
Why?
| | Renal Dialysis | 1 | 2023 | 378 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2001 | 709 | 0.040 |
Why?
| | Gastrectomy | 1 | 2020 | 82 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 369 | 0.040 |
Why?
| | Hemangioma, Cavernous | 1 | 1999 | 16 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 351 | 0.040 |
Why?
| | HLA Antigens | 1 | 2020 | 230 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 574 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1794 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 2995 | 0.040 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 122 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 349 | 0.040 |
Why?
| | Pilot Projects | 2 | 2014 | 1419 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2005 | 2513 | 0.040 |
Why?
| | Obesity | 2 | 2022 | 2746 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 311 | 0.040 |
Why?
| | Anatomic Variation | 1 | 2017 | 5 | 0.040 |
Why?
| | Nervous System | 1 | 1998 | 66 | 0.040 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2017 | 27 | 0.040 |
Why?
| | Mammary Glands, Animal | 2 | 1988 | 124 | 0.040 |
Why?
| | Hepcidins | 1 | 2017 | 24 | 0.040 |
Why?
| | Pancreas Transplantation | 2 | 2009 | 68 | 0.040 |
Why?
| | Boston | 1 | 2017 | 76 | 0.040 |
Why?
| | Ferritins | 1 | 2017 | 61 | 0.040 |
Why?
| | Phosphatidylcholines | 2 | 1988 | 133 | 0.040 |
Why?
| | Hepatic Artery | 3 | 2003 | 55 | 0.040 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 525 | 0.040 |
Why?
| | Cardiovascular System | 1 | 1998 | 127 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1308 | 0.040 |
Why?
| | Communication | 1 | 2022 | 761 | 0.040 |
Why?
| | Sepsis | 1 | 2022 | 531 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 1231 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2020 | 1085 | 0.040 |
Why?
| | Fatigue | 1 | 2018 | 297 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 200 | 0.030 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 22 | 0.030 |
Why?
| | Acute-On-Chronic Liver Failure | 1 | 2015 | 6 | 0.030 |
Why?
| | Hepatorenal Syndrome | 1 | 2015 | 14 | 0.030 |
Why?
| | Cross Infection | 1 | 1998 | 205 | 0.030 |
Why?
| | Contrast Media | 2 | 2013 | 373 | 0.030 |
Why?
| | Contraindications | 2 | 2006 | 86 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 79 | 0.030 |
Why?
| | Benchmarking | 1 | 2016 | 172 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 811 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 2011 | 6561 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 300 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 867 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 131 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 481 | 0.030 |
Why?
| | Social Class | 1 | 2016 | 218 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 540 | 0.030 |
Why?
| | Mesothelioma | 2 | 1985 | 32 | 0.030 |
Why?
| | Peritoneal Neoplasms | 2 | 1985 | 53 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 2851 | 0.030 |
Why?
| | Genotype | 2 | 2013 | 1882 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2016 | 306 | 0.030 |
Why?
| | Constitution and Bylaws | 1 | 2013 | 1 | 0.030 |
Why?
| | Decision Trees | 1 | 1993 | 83 | 0.030 |
Why?
| | Equipment Failure | 1 | 1994 | 114 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1355 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 1991 | 490 | 0.030 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 60 | 0.030 |
Why?
| | Hospitals, Low-Volume | 1 | 2013 | 23 | 0.030 |
Why?
| | Hospitals, High-Volume | 1 | 2013 | 42 | 0.030 |
Why?
| | Rabbits | 1 | 2014 | 780 | 0.030 |
Why?
| | Viral Envelope Proteins | 1 | 2013 | 80 | 0.030 |
Why?
| | Certification | 1 | 2013 | 99 | 0.030 |
Why?
| | Clinical Protocols | 1 | 1993 | 238 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 554 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1474 | 0.030 |
Why?
| | Anxiety | 1 | 2018 | 845 | 0.020 |
Why?
| | Alcoholism | 1 | 2018 | 717 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 495 | 0.020 |
Why?
| | Documentation | 1 | 2013 | 175 | 0.020 |
Why?
| | Patient Readmission | 1 | 2016 | 634 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 546 | 0.020 |
Why?
| | Pregnancy | 2 | 2021 | 5691 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 1993 | 225 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 1993 | 683 | 0.020 |
Why?
| | Education | 1 | 2011 | 105 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1012 | 0.020 |
Why?
| | Biological Transport | 2 | 1988 | 382 | 0.020 |
Why?
| | Research Design | 1 | 2016 | 969 | 0.020 |
Why?
| | Workload | 1 | 2011 | 128 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1945 | 0.020 |
Why?
| | Folic Acid | 1 | 1991 | 161 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 311 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1993 | 290 | 0.020 |
Why?
| | Methotrexate | 1 | 1991 | 227 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 1998 | 942 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2004 | 1384 | 0.020 |
Why?
| | Cholagogues and Choleretics | 1 | 2009 | 10 | 0.020 |
Why?
| | Brain Death | 1 | 2009 | 29 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2010 | 73 | 0.020 |
Why?
| | Ursodeoxycholic Acid | 1 | 2009 | 22 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1989 | 135 | 0.020 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 399 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 965 | 0.020 |
Why?
| | Phosphatidylethanolamines | 1 | 1988 | 66 | 0.020 |
Why?
| | Blood Glucose | 1 | 1998 | 1939 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 523 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3174 | 0.020 |
Why?
| | Life Style | 1 | 2011 | 430 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1687 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 709 | 0.020 |
Why?
| | Health Policy | 1 | 2011 | 333 | 0.020 |
Why?
| | Methyltransferases | 1 | 1988 | 61 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 235 | 0.020 |
Why?
| | Breast | 1 | 1988 | 140 | 0.020 |
Why?
| | Gastroenterology | 1 | 2010 | 158 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2011 | 422 | 0.020 |
Why?
| | Needs Assessment | 1 | 2010 | 327 | 0.020 |
Why?
| | Betaine | 1 | 1988 | 64 | 0.020 |
Why?
| | Selenium Compounds | 1 | 1987 | 21 | 0.020 |
Why?
| | Selenium | 1 | 1987 | 38 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 9491 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2011 | 556 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3588 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 1987 | 88 | 0.020 |
Why?
| | Fellowships and Scholarships | 1 | 2010 | 250 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2008 | 226 | 0.020 |
Why?
| | Clinical Competence | 1 | 2013 | 951 | 0.020 |
Why?
| | Survivors | 1 | 2009 | 418 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 4552 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 465 | 0.020 |
Why?
| | Podophyllotoxin | 1 | 1984 | 7 | 0.020 |
Why?
| | Etoposide | 1 | 1984 | 149 | 0.020 |
Why?
| | Carcinoma, Small Cell | 1 | 1984 | 158 | 0.020 |
Why?
| | Tissue Adhesions | 1 | 2004 | 31 | 0.010 |
Why?
| | Lung Transplantation | 1 | 2006 | 263 | 0.010 |
Why?
| | Lacerations | 1 | 2004 | 30 | 0.010 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2004 | 87 | 0.010 |
Why?
| | Abdomen | 1 | 2004 | 110 | 0.010 |
Why?
| | Curriculum | 1 | 2010 | 910 | 0.010 |
Why?
| | Internship and Residency | 1 | 2013 | 1001 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 1988 | 531 | 0.010 |
Why?
| | Intraoperative Complications | 1 | 2004 | 132 | 0.010 |
Why?
| | Angiography | 1 | 2003 | 185 | 0.010 |
Why?
| | Inflammation | 1 | 1993 | 2566 | 0.010 |
Why?
| | Erythrocytes | 1 | 1988 | 641 | 0.010 |
Why?
| | Hepatitis C Antibodies | 1 | 2002 | 10 | 0.010 |
Why?
| | Azathioprine | 1 | 2001 | 51 | 0.010 |
Why?
| | Blood Pressure | 1 | 2008 | 1664 | 0.010 |
Why?
| | Spleen | 1 | 2003 | 510 | 0.010 |
Why?
| | Ischemia | 1 | 2003 | 374 | 0.010 |
Why?
| | Secondary Prevention | 1 | 2001 | 227 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2003 | 398 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2003 | 290 | 0.010 |
Why?
| | APACHE | 1 | 1998 | 61 | 0.010 |
Why?
| | Imaging, Three-Dimensional | 1 | 2001 | 499 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 215 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1998 | 218 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1795 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1983 | 1390 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1984 | 2220 | 0.010 |
Why?
| | Combined Modality Therapy | 2 | 1985 | 1166 | 0.010 |
Why?
| | Pteroylpolyglutamic Acids | 1 | 1991 | 1 | 0.010 |
Why?
| | Tetrahydrofolates | 1 | 1991 | 11 | 0.010 |
Why?
| | Phosphatidylethanolamine N-Methyltransferase | 1 | 1988 | 8 | 0.010 |
Why?
| | Hemicholinium 3 | 1 | 1988 | 2 | 0.010 |
Why?
| | Dinitrophenols | 1 | 1988 | 7 | 0.010 |
Why?
| | Ouabain | 1 | 1988 | 15 | 0.010 |
Why?
| | 2,4-Dinitrophenol | 1 | 1988 | 10 | 0.010 |
Why?
| | Methylation | 1 | 1988 | 204 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1988 | 185 | 0.010 |
Why?
| | Selenium Radioisotopes | 1 | 1987 | 2 | 0.000 |
Why?
| | Selenious Acid | 1 | 1987 | 2 | 0.000 |
Why?
| | Selenomethionine | 1 | 1987 | 3 | 0.000 |
Why?
| | Lactation | 1 | 1988 | 160 | 0.000 |
Why?
| | Milk | 1 | 1988 | 125 | 0.000 |
Why?
| | Epithelium | 1 | 1988 | 305 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1988 | 1094 | 0.000 |
Why?
| | Drug Evaluation | 1 | 1984 | 81 | 0.000 |
Why?
| | Kinetics | 1 | 1988 | 1624 | 0.000 |
Why?
| | Asbestos | 1 | 1983 | 20 | 0.000 |
Why?
| | Laparotomy | 1 | 1983 | 106 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1988 | 963 | 0.000 |
Why?
| | Palliative Care | 1 | 1985 | 629 | 0.000 |
Why?
|
|
Pomfret's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|